Kymera Therapeutics, Inc. (KYMR) Form 10-Q — Oct 29, 2026
Kymera Therapeutics filed its Q3 2026 10-Q reporting a net loss of $132.0 million, wider than $82.2 million a year ago, as R&D spending jumped 73% to $128.5 million driven largely by the STAT6 program's Phase 2b trials in atopic dermatitis and asthma. Nine-month collaboration revenue more than doubled to $99.4 million, including a $45.0 million Gilead option exercise payment and a $20.0 million Sanofi milestone. The company holds $1,646 million in cash, equivalents and marketable securities and says this funds operations into 2029, beyond multiple clinical inflection points.
Key figures
- Revenue
- 99365000
- Total Debt
- 0
- Total Assets
- 1767269000
- Cash Position
- 373374000
- Shares Outstanding
- 85371397
- Runway
- into 2029
- Atm capacity
- 500000000
- Q3 rd expense
- 128509000
- Gilead upfront
- 40000000
- Atm shares sold
- 2032140
- Q3 2025 rd expense
- 74094000
- Accumulated deficit
- 1328405000
- Atm gross proceeds sold
- 219900000
- Nine month 2025 revenue
- 36341000
- Q3 collaboration revenue
- 0
- Gilead remaining milestones
- 665000000
- Q3 2025 collaboration revenue
- 2764000
- Cash cash and securities total
- 1646000000
- Gilead option exercise payment
- 45000000
- Prefunded warrants outstanding
- 15815253
- Sanofi remaining irak4 milestones
- 955000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.